肠道菌群在多囊卵巢综合征胰岛素抵抗中的作用机制

doi:10.12280/gjszjk.20200654

摘要/Abstract

摘要：

多囊卵巢综合征（PCOS）是一种高度异质性的妇科内分泌疾病,临床表现多为排卵障碍、月经失调、多毛、痤疮甚至不孕,常伴有肥胖、胰岛素抵抗（IR）、血脂异常等代谢性疾病,其发病机制尚不明确。IR是PCOS的主要病理基础,与性激素分泌异常、卵泡发育异常、子宫内膜容受性降低等生殖功能改变密切相关。肠道菌群被称为人体第二基因组,在维持宿主内环境的稳态中发挥多种功能,如阻止病原体入侵宿主,调节营养物质吸收和代谢,维持机体免疫系统、神经系统的稳定性等。近年来,许多研究报道肠道菌群组成改变可通过内毒素血症、胆汁酸、慢性低度炎症等多种途径引起IR,从而促进PCOS的发生发展。

关键词: 多囊卵巢综合征, 胰岛素抵抗, 肠道菌群, 代谢, 治疗

Abstract:

Polycystic ovary syndrome (PCOS) is a highly heterogeneous gynecological endocrine disease with clinical manifestations of ovulation disorders, menstrual disorders, hirsute, acne and even infertility. It is often accompanied by metabolic disorders such as obesity, insulin resistance (IR) and dyslipidemia. The pathogenesis of PCOS remains unclear. IR is the main pathological basis of PCOS, which is closely related to the changes of reproductive function such as abnormal level of sex hormones, abnormal follicle development and the reduced endometrial receptivity. Gut microbiome, known as the "second genome of human body", plays a variety of functions in maintaining the homeostasis of the host′s internal environment, such as preventing pathogens from invading the host, regulating absorption and metabolism of nutritional materials, and maintaining the stability of immune system and nervous system. In recent years, many studies have reported that the changes of gut microbiome composition can cause IR through endotoxemia, bile acid, chronic low-grade inflammation and other ways, thus promoting the occurrence and development of PCOS.

Key words: Polycystic ovary syndrome, Insulin resistance, Gut microbiome, Metabolism, Therapy

柴宜红, 杨盼盼, 张学红. 肠道菌群在多囊卵巢综合征胰岛素抵抗中的作用机制[J]. 国际生殖健康/计划生育, 2021, 40(4): 334-338.

CHAI Yi-hong, YANG Pan-pan, ZHANG Xue-hong. Research Progress on the Mechanism of Gastrointestinal Microbiome in Insulin Resistance of Polycystic Ovary Syndrome[J]. Journal of International Reproductive Health/Family Planning, 2021, 40(4): 334-338.

图/表 1

参考文献 32

[1]	Bannigida DM, Nayak BS, Vijayaraghavan R. Insulin resistance and oxidative marker in women with PCOS[J]. Arch Physiol Biochem, 2020, 126(2):183-186. doi: 10.1080/13813455.2018. 1499120. doi: 10.1080/13813455.2018.1499120 pmid: 30450993
[2]	Victor VM, Rovira-Llopis S, Bañuls C, et al. Insulin Resistance in PCOS Patients Enhances Oxidative Stress and Leukocyte Adhesion: Role of Myeloperoxidase[J]. PLoS One, 2016, 11(3):e0151960. doi: 10.1371/journal.pone.0151960. doi: 10.1371/journal.pone.0151960 URL
[3]	Oróstica L, García P, Vera C, et al. Effect of TNF-α on Molecules Related to the Insulin Action in Endometrial Cells Exposed to Hyperandrogenic and Hyperinsulinic Conditions Characteristics of Polycystic Ovary Syndrome[J]. Reprod Sci, 2018, 25(7):1000-1009. doi: 10.1177/1933719117732157. doi: 10.1177/1933719117732157 pmid: 28946816
[4]	Gourgari E, Lodish M, Shamburek R, et al. Lipoprotein Particles in Adolescents and Young Women With PCOS Provide Insights Into Their Cardiovascular Risk[J]. J Clin Endocrinol Metab, 2015, 100(11):4291-4298. doi: 10.1210/jc.2015-2566. doi: 10.1210/jc.2015-2566 pmid: 26371381
[5]	Carvalho L, Ferreira CN, de Oliveira D, et al. Haptoglobin levels, but not Hp1-Hp2 polymorphism, are associated with polycystic ovary syndrome[J]. J Assist Reprod Genet, 2017, 34(12):1691-1698. doi: 10.1007/s10815-017-1030-3. doi: 10.1007/s10815-017-1030-3 URL
[6]	Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences[J]. Metabolism, 2018, 86:33-43. doi: 10.1016/j.metabol.2017.09.016. doi: 10.1016/j.metabol.2017.09.016 URL
[7]	Torres PJ, Siakowska M, Banaszewska B, et al. Gut Microbial Diversity in Women With Polycystic Ovary Syndrome Correlates With Hyperandrogenism[J]. J Clin Endocrinol Metab, 2018, 103(4):1502-1511. doi: 10.1210/jc.2017-02153. doi: 10.1210/jc.2017-02153 pmid: 29370410
[8]	Qi X, Yun C, Sun L, et al. Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome[J]. Nat Med, 2019, 25(8):1225-1233. doi: 10.1038/s41591-019-0509-0. doi: 10.1038/s41591-019-0509-0 URL
[9]	Zeng B, Lai Z, Sun L, et al. Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study[J]. Res Microbiol, 2019, 170(1):43-52. doi: 10.1016/j.resmic.2018.09.002. doi: S0923-2508(18)30138-4 pmid: 30292647
[10]	Hallajzadeh J, Khoramdad M, Karamzad N, et al. Metabolic syndrome and its components among women with polycystic ovary syndrome: a systematic review and meta-analysis[J]. J Cardiovasc Thorac Res, 2018, 10(2):56-69. doi: 10.15171/jcvtr.2018.10. doi: 10.15171/jcvtr.2018.10 pmid: 30116503
[11]	Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance[J]. Diabetes, 2007, 56(7):1761-1772. doi: 10.2337/db06-1491. doi: 10.2337/db06-1491 URL
[12]	Herrema H, IJzerman RG, Nieuwdorp M. Emerging role of intestinal microbiota and microbial metabolites in metabolic control[J]. Diabetologia, 2017, 60(4):613-617. doi: 10.1007/s00125-016-4192-0. doi: 10.1007/s00125-016-4192-0 pmid: 28013341
[13]	Pedersen HK, Gudmundsdottir V, Nielsen HB, et al. Human gut microbes impact host serum metabolome and insulin sensitivity[J]. Nature, 2016, 535(7612):376-381. doi: 10.1038/nature18646. doi: 10.1038/nature18646 URL
[14]	Tremellen K, Pearce K. Dysbiosis of Gut Microbiota (DOGMA)--a novel theory for the development of Polycystic Ovarian Syndrome[J]. Med Hypotheses, 2012, 79(1):104-112. doi: 10.1016/j.mehy.2012.04.016. doi: 10.1016/j.mehy.2012.04.016 pmid: 22543078
[15]	Guadagnini D, Rocha GZ, Santos A, et al. Microbiota determines insulin sensitivity in TLR2-KO mice[J]. Life Sci, 2019, 234:116793. doi: 10.1016/j.lfs.2019.116793. doi: S0024-3205(19)30720-9 pmid: 31465735
[16]	Zhao Y, Zhang C, Huang Y, et al. Up-regulated expression of WNT5a increases inflammation and oxidative stress via PI3K/AKT/NF-κB signaling in the granulosa cells of PCOS patients[J]. J Clin Endocrinol Metab, 2015, 100(1):201-211. doi: 10.1210/jc.2014-2419. doi: 10.1210/jc.2014-2419 pmid: 25303486
[17]	Andreasen AS, Larsen N, Pedersen-Skovsgaard T, et al. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects[J]. Br J Nutr, 2010, 104(12):1831-1838. doi: 10.1017/S0007114510002874. doi: 10.1017/S0007114510002874 URL
[18]	Murugesan S, Nirmalkar K, Hoyo-Vadillo C, et al. Gut microbiome production of short-chain fatty acids and obesity in children[J]. Eur J Clin Microbiol Infect Dis, 2018, 37(4):621-625. doi: 10.1007/s10096-017-3143-0. doi: 10.1007/s10096-017-3143-0 URL
[19]	Gao Z, Yin J, Zhang J, et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice[J]. Diabetes, 2009, 58(7):1509-1517. doi: 10.2337/db08-1637. doi: 10.2337/db08-1637 URL
[20]	Zhang J, Sun Z, Jiang S, et al. Probiotic Bifidobacterium lactis V9 Regulates the Secretion of Sex Hormones in Polycystic Ovary Syndrome Patients through the Gut-Brain Axis[J]. mSystems, 2019, 4(2):e00017-19. doi: 10.1128/mSystems.00017-19. doi: 10.1128/mSystems.00017-19
[21]	Cicione C, Degirolamo C, Moschetta A. Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver[J]. Hepatology, 2012, 56(6):2404-2411. doi: 10.1002/hep.25929. doi: 10.1002/hep.25929 URL
[22]	Koh A, Molinaro A, Ståhlman M, et al. Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1[J]. Cell, 2018, 175(4):947-961. e17. doi: 10.1016/j.cell.2018. 09.055. doi: 10.1016/j.cell.2018. 09.055 URL
[23]	Zhang CM, Zhao Y, Li R, et al. Metabolic heterogeneity of follicular amino acids in polycystic ovary syndrome is affected by obesity and related to pregnancy outcome[J]. BMC Pregnancy Childbirth, 2014, 14:11. doi: 10.1186/1471-2393-14-11. doi: 10.1186/1471-2393-14-11 URL
[24]	Sherman SB, Sarsour N, Salehi M, et al. Prenatal androgen exposure causes hypertension and gut microbiota dysbiosis[J]. Gut Microbes, 2018, 9(5):400-421. doi: 10.1080/19490976.2018. 1441664. doi: 10.1080/19490976.2018. 1441664
[25]	Torres PJ, Skarra DV, Ho BS, et al. Letrozole treatment of adult female mice results in a similar reproductive phenotype but distinct changes in metabolism and the gut microbiome compared to pubertal mice[J]. BMC Microbiol, 2019, 19(1):57. doi: 10.1186/s12866-019-1425-7. doi: 10.1186/s12866-019-1425-7 pmid: 30871463
[26]	Yurtdaş G, Akdevelioğlu Y. A New Approach to Polycystic Ovary Syndrome: The Gut Microbiota[J]. J Am Coll Nutr, 2020, 39(4):371-382. doi: 10.1080/07315724.2019.1657515. doi: 10.1080/07315724.2019.1657515 pmid: 31513473
[27]	Lin T, Li S, Xu H, et al. Gastrointestinal hormone secretion in women with polycystic ovary syndrome: an observational study[J]. Hum Reprod, 2015, 30(11):2639-2644. doi: 10.1093/humrep/dev231. doi: 10.1093/humrep/dev231 URL
[28]	Liu R, Zhang C, Shi Y, et al. Dysbiosis of Gut Microbiota Associated with Clinical Parameters in Polycystic Ovary Syndrome[J]. Front Microbiol, 2017, 8:324. doi: 10.3389/fmicb.2017.00324. doi: 10.3389/fmicb.2017.00324
[29]	Saydam BO, Yildiz BO. Gut-Brain Axis and Metabolism in Polycystic Ovary Syndrome[J]. Curr Pharm Des, 2016, 22(36):5572-5587. doi: 10.2174/1381612822666160715143933. doi: 10.2174/1381612822666160715143933 URL
[30]	Singh RK, Chang HW, Yan D, et al. Influence of diet on the gut microbiome and implications for human health[J]. J Transl Med, 2017, 15(1):73. doi: 10.1186/s12967-017-1175-y. doi: 10.1186/s12967-017-1175-y URL
[31]	Sun L, Xie C, Wang G, et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin[J]. Nat Med, 2018, 24(12):1919-1929. doi: 10.1038/s41591-018-0222-4. doi: 10.1038/s41591-018-0222-4 URL
[32]	Ahmadi S, Jamilian M, Karamali M, et al. Probiotic supplementation and the effects on weight loss, glycaemia and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial[J]. Hum Fertil(Camb), 2017, 20(4):254-261. doi: 10.1080/14647273.2017.1283446. doi: 10.1080/14647273.2017.1283446